HLN:LSE-Haleon PLC (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 278.80

Change

-7.55 (-2.64)%

Market Cap

GBX 25.55B

Volume

0.02B

Avg Analyst Target

GBX 282.50 (+1.33%)

Avg User Target

GBX
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


HLN Stock Forecast & Price:
Based on the Haleon PLC stock forecasts from 3 analysts, the average analyst target price for Haleon PLC is GBX 282.50 over the next 12 months. Haleon PLC’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Haleon PLC is Slightly Bullish , which is based on 5 positive signals and 3 negative signals. At the last closing, Haleon PLC’s stock price was GBX 278.80. Haleon PLC’s stock price has changed by +5.03% over the past week, +4.69% over the past month and 0% over the last year.

About Haleon PLC (HLN:LSE)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

+31.50 (+2.60%)

GBX2.66B 9.09 5.27
INDV:LSE Indivior PLC

-0.80 (-0.29%)

GBX1.92B 14.62 5.99
HCM:LSE HUTCHMED China Ltd

+3.30 (+1.99%)

GBX1.33B 17.41 -2.31
AMYT:LSE Amryt Pharma plc

N/A

GBX0.46B N/A 260.86
APH:LSE Alliance Pharma plc

N/A

GBX0.33B 30.45 11.38
BXP:LSE Beximco Pharmaceuticals Limite..

N/A

GBX0.32B 6.50 0.09
BMK:LSE Benchmark Holdings Plc

-1.30 (-3.17%)

GBX0.29B N/A 12.56
ANCR:LSE Animalcare Group Plc

-15.00 (-5.41%)

GBX0.16B 3,350.00 17.57
AGY:LSE Allergy Therapeutics

N/A

GBX0.12B 53.13 306.41
ZOE:LSE Zoetic International Plc

N/A

GBX0.08B N/A 64.52

ETFs Containing HLN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 25.55B 100% A+ 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.29 50% F 26% F
Price/Book Ratio 0.95 72% C- 58% F
Price / Cash Flow Ratio 18.84 17% F 17% F
EV/EBITDA 16.25 22% F 15% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 6.10% 72% C- 73% C
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.